While CLL B-cells from previously untreated CLL patients express significantly higher levels of constitutively phosphorylated Axl compared to normal B-cells from healthy individuals [17, 18], activation status of this RTK in relapsed/refractory CLL B-cells from the ibrutinib cohort has not yet been reported. The gene discussed is AXL; the disease is B-cell chronic lymphocytic leukemia.